Liu Baoxin, Yan Han, Guo Rong, Liu Xueyuan, Li Xiankai, Xu Yawei
1. Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
2. Department of Neurology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Int J Med Sci. 2014 Jun 22;11(9):905-17. doi: 10.7150/ijms.8877. eCollection 2014.
Several social economic factors play important roles in treatments of ST-elevation myocardial infarction (STEMI) and finally influence the clinical outcomes. The basic social medical insurance (BSMI) is an important economic factor in China's medical system. However, the impact of BSMI on clinical outcomes in STEMI patients has not been explored yet. The aim of this study is to investigate whether BSMI is a predictor of clinical outcomes in the patients with STEMI in Shanghai, China.
In this retrospective study, 681 STEMI patients from different areas in Shanghai were classified into four groups: new rural cooperative medical scheme (NCMS) group, urban resident basic medical insurance scheme (URBMI) group, urban employee basic medical insurance scheme (UEBMI) group and UNINSURED group, major adverse events (cardiac death, nonfatal reinfarction, clinically driven target lesion revascularization/target vessel revascularization, stroke, heart failure) were regarded as study endpoints to determine whether BSMI was a prognostic factor.
During a mean follow-up of 36 months, the incidence of major adverse events was significantly higher in NCMS patients (64; 38.8%) compared with the other groups: URBMI (47; 24.6%); UEBMI (28; 15.6%); UNISURED (40; 27.6%). Similarly, cardiac mortality was also higher in NCMS group (19; 11.5%). A Kaplan-Meier survival analysis revealed significantly lower event-free survival rate for major adverse events (p < 0.001) and cardiac mortality (p = 0.01) in NCMS group. Multivariate Cox regression analysis revealed that BSMI was an important prognostic factor in STEMI patients.
These results demonstrate that BSMI is closely associated with the major adverse events-free survival rate at 36-month follow-up in the STEMI patients under the current policies in Shanghai, China.
多种社会经济因素在ST段抬高型心肌梗死(STEMI)的治疗中发挥重要作用,并最终影响临床结局。基本社会医疗保险(BSMI)是中国医疗体系中的一个重要经济因素。然而,BSMI对STEMI患者临床结局的影响尚未得到探讨。本研究的目的是调查在中国上海,BSMI是否为STEMI患者临床结局的一个预测因素。
在这项回顾性研究中,来自上海不同地区的681例STEMI患者被分为四组:新型农村合作医疗(NCMS)组、城镇居民基本医疗保险(URBMI)组、城镇职工基本医疗保险(UEBMI)组和未参保组,将主要不良事件(心源性死亡、非致死性再梗死、临床驱动的靶病变血运重建/靶血管血运重建、卒中、心力衰竭)视为研究终点,以确定BSMI是否为一个预后因素。
在平均36个月的随访期间,NCMS患者的主要不良事件发生率(64例;38.8%)显著高于其他组:URBMI组(47例;24.6%);UEBMI组(28例;15.6%);未参保组(40例;27.6%)。同样,NCMS组的心源性死亡率也更高(19例;11.5%)。Kaplan-Meier生存分析显示,NCMS组主要不良事件(p<0.001)和心源性死亡(p=0.01)的无事件生存率显著更低。多因素Cox回归分析显示,BSMI是STEMI患者的一个重要预后因素。
这些结果表明,在中国上海当前政策下,BSMI与STEMI患者36个月随访时的主要不良事件无生存率密切相关。